Zoledronic acid in the treatment of early-stage breast cancer: Is there a final verdict?

Current Oncology Reports

Volumn 14, Issue 1, 2012, Pages 35-43

  Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticancer; Bisphosphonate; Breast cancer; Zoledronic acid

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; OSTEOLYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; SURVIVAL RATE;

EID: 84857637022     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0209-5     Document Type: Article

References (94)

1. American Cancer Society. Global cancer facts & figures. 2nd ed. Atlanta: American Cancer Society; 2011.
2. A Jemal R Siegel E Ward Y Hao J Xu T Murray, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin. 58 2 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
3. RE Coleman 2009 Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer. 45 11 1909 15 19447606 10.1016/j.ejca.2009.04.022 1:CAS:528:DC%2BD1MXotFCjs7s%3D
4. •• Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract S4-5. First efficacy data from the AZURE trial evaluating a tapered regimen of ZOL in combination with standard adjuvant therapy for stage II/III breast cancer, demonstrating DFS and OS benefits with ZOL in women with established postmenopausal status.
5. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-1405.
6. •• Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91.First efficacy data from the ABCSG-12 trial and first prospective demonstration of DFS benefits from adding ZOL to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer.
7. MY Kim T Oskarsson S Acharyya, et al. 2009 Tumor self-seeding by circulating cancer cells Cell. 139 7 1315 26 20064377 10.1016/j.cell.2009.11.025
8. GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer. 2 8 584 93 12154351 10.1038/nrc867 1:CAS:528:DC%2BD38XlslGqsLo%3D (Pubitemid 37328925)
9. L Norton J Massague 2006 Is cancer a disease of self-seeding? Nat Med. 12 8 875 8 16892025 10.1038/nm0806-875 1:CAS:528:DC%2BD28Xnsl2itLk%3D (Pubitemid 44175132)
10. MB Meads LA Hazlehurst WS Dalton 2008 The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance Clin Cancer Res. 14 9 2519 26 18451212 10.1158/1078-0432.CCR-07-2223 1:CAS:528:DC%2BD1cXlsV2qs74%3D
11. • Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22(5):941-50. Explanations of the potential role of the bone marrow niche in harboring cancer cells and facilitating their resistance to systemic therapy. (Pubitemid 351689875)
12. • Bidard FC, Kirova YM, Vincent-Salomon A, et al. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol. 2009;20(11):1836-41. Evidence of the negative prognostic significance of disseminated tumor cells in patients undergoing adjuvant therapy for breast cancer.
13. M Cristofanilli DF Hayes GT Budd, et al. 2005 Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer J Clin Oncol. 23 7 1420 30 15735118 10.1200/JCO.2005.08.140
14. AM Brufsky LD Bosserman RR Caradonna, et al. 2009 Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer. 9 2 77 85 19433387 10.3816/CBC.2009.n.015 1:CAS:528:DC%2BD1MXmtlahtLY%3D
15. •• Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol. 2010;21:2188-94. Data from the ZO-FAST trial demonstrating DFS benefits from adding ZOL to adjuvant aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer.
16. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol. 26 30 4875 82 18725648 10.1200/JCO.2008.16.3832 1:CAS:528:DC%2BD1cXhtlGitrzO
17. Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up [poster]. Presented at American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8-10, 2009; San Francisco, CA. Abstract 213.
18. CL Shapiro S Halabi V Hars L Archer D Weckstein J Kirshner, et al. 2011 Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809 Eur J Cancer. 47 5 683 9 21324674 10.1016/j.ejca.2010.11.024 1:CAS:528:DC%2BC3MXisFKgsb8%3D
19. RG Russell 2007 Bisphosphonates: mode of action and pharmacology Pediatrics. 119 suppl 2 S150 S62 17332236 10.1542/peds.2006-2023H (Pubitemid 46397937)
20. KL Kavanagh K Guo JE Dunford, et al. 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci U S A. 103 20 7829 34 16684881 10.1073/pnas.0601643103 1:CAS:528: DC%2BD28XlsVGksL0%3D
21. JE Dunford K Thompson FP Coxon, et al. 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther. 296 2 235 42 11160603 1:CAS:528:DC%2BD3MXoslaluw%3D%3D (Pubitemid 32112446)
22. JR Green A Guenther 2011 The backbone of progress-preclinical studies and innovations with zoledronic acid Crit Rev Oncol Hematol. 77 suppl 1 S3 S12 21353178 10.1016/S1040-8428(11)70003-8
23. MC Winter I Holen RE Coleman 2008 Exploring the anti-tumour activity of bisphosphonates in early breast cancer Cancer Treat Rev. 34 5 453 75 18423992 10.1016/j.ctrv.2008.02.004 1:CAS:528:DC%2BD1cXosVymur0%3D
24. N Caccamo S Meraviglia F Scarpa, et al. 2008 Aminobisphosphonate- activated gammadelta T cells in immunotherapy of cancer: doubts no more Expert Opin Biol Ther. 8 7 875 83 18549319 10.1517/14712598.8.7.875 1:CAS:528:DC%2BD1cXntFOku7c%3D (Pubitemid 352007000)
25. JP Coxon GM Oades RS Kirby KW Colston 2004 Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation BJU Int. 94 1 164 70 15217454 10.1111/j.1464-4096.2004.04831.x 1:CAS:528:DC%2BD2cXmvVeiu74%3D (Pubitemid 38980328)
26. PI Croucher R De Hendrik MJ Perry, et al. 2003 Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival J Bone Miner Res. 18 3 482 92 12619933 10.1359/jbmr.2003.18.3.482 1:CAS:528:DC%2BD3sXitVyrsL0%3D (Pubitemid 36241065)
27. F Daubine C Le Gall J Gasser, et al. 2007 Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis J Natl Cancer Inst. 99 4 322 30 17312309 10.1093/jnci/djk054 1:CAS:528:DC%2BD2sXjsVeitrc%3D (Pubitemid 47073494)
28. C Denoyelle L Hong JP Vannier, et al. 2003 New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects Br J Cancer. 88 10 1631 40 10.1038/sj.bjc. 66009256600925 12771933 10.1038/sj.bjc.6600925 1:CAS:528:DC%2BD3sXktVentrs%3D (Pubitemid 36713793)
29. S Kimura J Kuroda H Segawa, et al. 2004 Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines Int J Hematol. 79 1 37 43 14979476 10.1007/BF02983531 1:CAS:528:DC%2BD2cXhslGntbY%3D (Pubitemid 38182199)
30. • Michailidou M, Brown HK, Lefley DV, et al. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J Vasc Res. 2010;47(6):481-93. Preclinical insights into the anticancer activities of bisphosphonates.
31. HL Neville-Webbe RE Coleman I Holen 2010 Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction Br J Cancer. 102 6 1010 7 20160726 10.1038/sj.bjc.6605579 1:CAS:528:DC%2BC3cXjt1ynu7k%3D
32. HL Neville-Webbe M Gnant RE Coleman 2010 Potential anticancer properties of bisphosphonates Semin Oncol. 37 suppl 1 S53 S65 20682373 10.1053/j. seminoncol.2010.06.008 1:CAS:528:DC%2BC3cXht1SnurrF
33. PD Ottewell B Deux H Monkkonen, et al. 2008 Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo Clin Cancer Res. 14 14 4658 66 18628481 10.1158/1078-0432.CCR- 07-1545 1:CAS:528:DC%2BD1cXosFGiurw%3D
34. PD Ottewell DV Lefley SS Cross, et al. 2010 Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model Int J Cancer. 126 2 522 32 19621384 10.1002/ijc.24756 1:CAS:528:DC%2BD1MXhsFGjsrvL
35. • Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008;100(16):1167-78. Preclinical insights into the anticancer activities of bisphosphonates.
36. • Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009;58(1):31-8. Insights into the immunomodulatory effects of ZOL and anticancer cytotoxicity of gamma-delta T cells.
37. D Santini B Vincenzi S Galluzzo, et al. 2007 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res. 13 15 pt 1 4482 6 17671133 10.1158/1078-0432.CCR-07-0551 1:CAS:528:DC%2BD2sXotlGqtb4%3D (Pubitemid 47219717)
38. K Sato S Kimura H Segawa, et al. 2005 Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy Int J Cancer. 116 1 94 9 15756684 10.1002/ijc.20987 1:CAS:528:DC%2BD2MXls1Kjt7w%3D (Pubitemid 40827760)
39. B Vincenzi D Santini G Dicuonzo, et al. 2005 Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients J Interferon Cytokine Res. 25 3 144 51 15767788 10.1089/jir.2005.25.144 1:CAS:528:DC%2BD2MXit1KnsL4%3D (Pubitemid 40354834)
40. T Yuasa S Kimura E Ashihara, et al. 2007 Zoledronic acid-a multiplicity of anti-cancer action Curr Med Chem. 14 20 2126 35 17691952 10.2174/ 092986707781389600 1:CAS:528:DC%2BD2sXptV2hs7c%3D (Pubitemid 47578153)
41. A Ibrahim N Scher G Williams, et al. 2003 Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases Clin Cancer Res. 9 7 2394 9 12855610 1:CAS:528:DC%2BD3sXlt1ykur4%3D (Pubitemid 36842077)
42. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature. 423 6937 337 42 12748652 10.1038/nature01658 1:CAS:528:DC%2BD3sXjs1ynu7g%3D (Pubitemid 40852708)
43. Xgeva (denosumab) injection, for subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2010.
44. Xgeva (denosumab) granted marketing authorization in the European Union [press release]. Available at http://www.prnewswire.com/news-releases/xgeva- denosumab-granted-marketing-authorization-in-the-european-union-125624563.html. Accessed July 2011
45. A Goldhirsch JN Ingle RD Gelber, et al. 2009 Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 Ann Oncol. 20 8 1319 29 19535820 10.1093/annonc/mdp322 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D
46. CL Shapiro J Manola M Leboff 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol. 19 14 3306 11 11454877 1:CAS:528:DC%2BD3MXlvVamsr4%3D (Pubitemid 32642182)
47. L Del Mastro M Venturini MR Sertoli R Rosso 1997 Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications Breast Cancer Res Treat. 43 2 183 90 9131274 10.1023/A:1005792830054 (Pubitemid 27165879)
48. M Gnant 2009 Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials Curr Cancer Drug Targets. 9 7 824 33 20025570 10.2174/156800909789760267 1:CAS:528:DC%2BD1MXhsFGqtLrL
49. AM Jimenez-Gordo P de las Heras, et al. 2000 Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports Gynecol Oncol. 76 1 126 7 10.1006/gyno.1999.5641 10620455 10.1006/gyno.1999.5641 1:STN:280:DC%2BD3c%2FovVyksw%3D%3D (Pubitemid 30048333)
50. G Uncu S Benderli A Esmer 1996 Pregnancy during gonadotrophin-releasing hormone agonist therapy Aust N Z J Obstet Gynaecol. 36 4 484 5 9006841 10.1111/j.1479-828X.1996.tb02200.x 1:STN:280:DyaK2s7lvFGjsA%3D%3D (Pubitemid 26413507)
51. G Rannevik S Jeppsson O Johnell, et al. 2008 A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density Maturitas. 61 1-2 67 77 19434880 10.1016/j.maturitas.2008.09.010 1:STN:280:DC%2BD1MzjvVejsw%3D%3D
52. MR Sowers H Zheng D McConnell, et al. 2008 Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women J Clin Endocrinol Metab. 93 10 3847 52 18647803 10.1210/jc.2008-1056 1:CAS:528:DC%2BD1cXht1Gmur%2FF
53. JM Dixon L Renshaw O Young, et al. 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer J Clin Oncol. 26 10 1671 6 18375896 10.1200/JCO.2007.13.9279 1:CAS:528:DC%2BD1cXltlWhsrk%3D
54. KM Nicks TW Fowler NS Akel, et al. 2010 Bone turnover across the menopause transition : The role of gonadal inhibins Ann N Y Acad Sci. 1192 153 60 20392231 10.1111/j.1749-6632.2009.05349.x 1:CAS:528:DC%2BC3cXmsVSrsb0%3D
55. J Sirola H Kroger R Honkanen, et al. 2003 Factors affecting bone loss around menopause in women without HRT: a prospective study Maturitas. 45 3 159 67 12818460 10.1016/S0378-5122(03)00150-6 (Pubitemid 36724870)
56. C Brumsen SE Papapoulos P Lips, et al. 2002 Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension J Bone Miner Res. 17 6 1057 64 12054161 10.1359/jbmr.2002.17.6.1057 1:CAS:528:DC%2BD38Xks1Wktb0%3D (Pubitemid 34535144)
57. JP Devogelaer 2000 Long-lasting effect of pamidronate on bone metabolism in osteoporosis after stopping therapy J Musculoskelet Neuronal Interact. 1 2 149 51 15758510 1:CAS:528:DC%2BD3MXnt1antg%3D%3D
58. J Reginster HW Minne OH Sorensen, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int. 11 1 83 91 10663363 10.1007/s001980050010 1:CAS:528:DC%2BD3cXhvFGgsr0%3D (Pubitemid 30099515)
59. T Saarto L Vehmanen I Elomaa, et al. 2001 The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer Br J Cancer. 84 8 1047 51 11308252 10.1054/bjoc.2001.1729 1:CAS:528:DC%2BD3MXktFymur4%3D (Pubitemid 32448500)
60. M Tuppurainen K Harma M Komulainen, et al. 2010 Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up Maturitas. 66 4 423 30 20547017 10.1016/j.maturitas.2010.04.013 1:CAS:528:DC%2BC3cXptVWhsbs%3D
61. AD Anastasilakis KA Toulis DG Goulis, et al. 2009 Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis Horm Metab Res. 41 10 721 9 19536731 10.1055/s-0029-1224109 1:CAS:528:DC%2BD1MXhsVyrtrvM
62. • Benzaid I, Monkkonen H, Stresing V, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote v{gamma}9v{delta}2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71(13):4562-72. Insights into the immunomodulatory effects of ZOL and anticancer cytotoxicity of gamma-delta T cells.
63. Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol. 2011 [E-pub ahead of print].
64. V Stresing PG Fournier A Bellahcene, et al. 2011 Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase Bone. 48 2 259 66 20920623 10.1016/j.bone.2010. 09.035 1:CAS:528:DC%2BC3MXmvF2msQ%3D%3D
65. RD Clyburn P Reid CA Evans, et al. 2010 Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy Cancer Chemother Pharmacol. 65 5 969 78 19730863 10.1007/s00280-009-1106-6 1:CAS:528:DC%2BC3cXit1Gmur4%3D
66. •• Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421-8.Evidence for reduced persistence of disseminated tumor cells in women with early breast cancer receiving (neo)adjuvant ZOL plus chemotherapy compared with chemotherapy alone.
67. Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol. 2008;26(15 suppl):20s. Abstract 559.
68. B Rack J Juckstock EM Genss, et al. 2010 Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer Anticancer Res. 30 5 1807 13 20592383 1:CAS:528:DC%2BC3cXhtVWmu73N
69. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]. Presented at 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2048.
70. Greenberg S, Park JW, Melisko ME, et al. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated results [abstract]. J Clin Oncol. 2010;28(15 suppl):114s. Abstract 1002.
71. FC Bidard A Vincent-Salomon S Gomme, et al. 2008 Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse Clin Cancer Res. 14 11 3306 11 18519757 10.1158/1078-0432.CCR-07-4749 1:CAS:528:DC%2BD1cXmslygsL4%3D
72. S Braun K Pantel 2001 Clinical significance of occult metastatic cells in bone marrow of breast cancer patients Oncologist. 6 2 125 32 11306724 10.1634/theoncologist.6-2-125 1:STN:280:DC%2BD3Mzot12qtw%3D%3D (Pubitemid 32323451)
73. S Braun FD Vogl B Naume, et al. 2005 A pooled analysis of bone marrow micrometastasis in breast cancer N Engl J Med. 353 8 793 802 16120859 10.1056/NEJMoa050434 1:CAS:528:DC%2BD2MXovVKlu7s%3D (Pubitemid 41215488)
74. RE Coleman MC Winter D Cameron, et al. 2010 The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer. 102 1099 105 20234364 10.1038/sj.bjc.6605604 1:CAS:528:DC%2BC3cXjvFymtr0%3D
75. • Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;19(12):2007-11. Early evidence for the potential anticancer effects of an oral bisphosphonate, clodronate.
76. T Powles A Paterson E McCloskey, et al. 2006 Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Breast Cancer Res. 8 2 R13 16542503 10.1186/bcr1384 (Pubitemid 44376864)
77. T Saarto L Vehmanen P Virkkunen C Blomqvist 2004 Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients Acta Oncol. 43 7 650 6 15545185 10.1080/02841860410032885 1:CAS:528:DC%2BD2cXpsVSltrc%3D (Pubitemid 39563937)
78. RT Chlebowski Z Chen JA Cauley, et al. 2010 Oral bisphosphonate use and breast cancer incidence in postmenopausal women J Clin Oncol. 28 22 3582 90 20567009 10.1200/JCO.2010.28.2095 1:CAS:528:DC%2BC3cXhtFSksb3N
79. G Rennert M Pinchev HS Rennert 2010 Use of bisphosphonates and risk of postmenopausal breast cancer J Clin Oncol. 28 22 3577 81 20567021 10.1200/JCO.2010.28.1113 1:CAS:528:DC%2BC3cXhtFSksb3M
80. PA Newcomb A Trentham-Dietz JM Hampton 2010 Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk Br J Cancer. 102 5 799 802 20160722 10.1038/sj.bjc.6605555 1:CAS:528: DC%2BC3cXis1ygs70%3D
81. G Rennert M Pinchev HS Rennert SB Gruber 2011 Use of bisphosphonates and reduced risk of colorectal cancer J Clin Oncol. 29 9 1146 50 21321296 10.1200/JCO.2010.33.7485
82. U.S. National Institutes of Health. Clodronate with or without chemotherapy and/or hormonal therapy in treating women with stage I or stage II breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00009945?term= clodronate%2C+NSABP&rank=1. Accessed July 2011.
83. Data on file. East Hanover. NJ: Novartis Pharmaceuticals Corporation; 2010.
84. U.S. National Institutes of Health. Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. Available at http://clinicaltrials.gov/ct2/show/ NCT00127205?term=SWOG+0307&rank=2. Accessed July 2011.
85. Mobus V, Conrad B, Schneeweiss A, et al. Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer. J Clin Oncol. 2009;27(15s):Abstract 568.
86. U.S. National Institutes of Health. A study to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00196872?term= ibandronate%2C+GAIN&rank=1. Accessed July 2011.
87. Rothstein A. Denosumab safety FDA analysis. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ReproductiveHealthDrugsAdvisoryCommittee/UCM187083.pdf.
88. U.S. National Institutes of Health. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). http://clinicaltrials.gov/ct2/show/NCT01077154?term= NCT01077154&rank=1. Accessed July 2011.
89. U.S. National Institutes of Health. Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy. http://clinicaltrials.gov/ct2/show/NCT00556374?term=abcsg-18&rank= 1[1/6/2011. Accessed July 2011.
90. Goss PE, Barrios CH, Bell R, et al. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE) [poster]. Presented at Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL. Abstract TPS152.
91. de Boer R, Bundred N, Eidtman H, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The ZO-FAST study 5-year final follow-up [poster]. Presented at 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Poster P5-11-01.
92. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Overall survival with adjuvant zoledronic acid in premenopausal breast cancer patients with complete endocrine blockade-long-term results from ABCSG-12 [poster]. Presented at Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL. Abstract 520.
93. M Gnant B Mlineritsch H Stoeger, et al. 2011 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol. 12 7 631 41 10.1016/S1470-2045(11)70122-X 21641868 10.1016/S1470-2045(11)70122-X 1:CAS:528:DC%2BC3MXot1ejtLc%3D
94. Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]. Presented at 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 4082.